Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 2
2003 12
2004 8
2005 10
2006 9
2007 2
2008 10
2009 6
2010 8
2011 14
2012 12
2013 14
2014 13
2015 16
2016 15
2017 14
2018 10
2019 11
2020 10
2021 5
2022 9
2023 7
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 26044084

203 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASIS-HF Investigators. Eschalier R, et al. J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93. doi: 10.1016/j.jacc.2013.04.086. Epub 2013 Jun 27. J Am Coll Cardiol. 2013. PMID: 23810881 Free article. Clinical Trial.
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Rossignol P, et al. Circ Heart Fail. 2014 Jan;7(1):51-8. doi: 10.1161/CIRCHEARTFAILURE.113.000792. Epub 2013 Dec 2. Circ Heart Fail. 2014. PMID: 24297687 Clinical Trial.
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC. Butler J, et al. J Card Fail. 2012 Apr;18(4):265-81. doi: 10.1016/j.cardfail.2012.02.005. J Card Fail. 2012. PMID: 22464767
Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Carillo S, Zhang Y, Fay R, Angioi M, Vincent J, Sutradhor SC, Ahmed A, Pitt B, Zannad F. Carillo S, et al. Arch Cardiovasc Dis. 2014 Mar;107(3):149-57. doi: 10.1016/j.acvd.2014.01.010. Epub 2014 Mar 11. Arch Cardiovasc Dis. 2014. PMID: 24630753 Free article.
Eplerenone in patients with systolic heart failure and mild symptoms.
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Zannad F, et al. N Engl J Med. 2011 Jan 6;364(1):11-21. doi: 10.1056/NEJMoa1009492. Epub 2010 Nov 14. N Engl J Med. 2011. PMID: 21073363 Free article. Clinical Trial.
203 results